Skip to main
PSTV
PSTV logo

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc. is making strides in the commercialization of its CNSide Diagnostic platform, with expanded manufacturing capacity and enhanced leadership that supports compliance and scalability. The company's collaboration with NCI-Designated Cancer Centers and a favorable policy agreement with UnitedHealthcare bolster its payor coverage and market readiness, indicating strong early adoption prospects. Furthermore, the company secured an $18 million grant from the Cancer Prevention and Research Institute of Texas to advance research on leptomeningeal metastases, reflecting a solid commitment to growth and innovation in its drug development pipeline.

Bears say

Plus Therapeutics Inc faces significant risks that adversely affect its stock outlook, primarily centered around the potential failure of its product candidates to demonstrate safety and efficacy during clinical trials. Furthermore, challenges in obtaining regulatory approval for commercial sale and securing suitable reimbursement could hinder the company's financial viability. Although pro forma EPS reported a net income of $1.2 million, it fell short of estimates and consensus predictions, indicating underlying financial weaknesses that contribute to the negative sentiment surrounding the stock.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.